The Future of the U.S. Biosimilars Market:
Development, Education, and Utilization
Friends of Cancer Research and Duke Margolis Center for Health Policy will convene a half-day forum bringing together clinicians, originator and biosimilar drug sponsors, advocates, regulators, and payers to tackle remaining uncertainty surrounding the future of the U.S. biosimilars market.
Draft Meeting Agenda
9:00 a.m. - Welcome and Introduction
Jeff Allen, Friends of Cancer Research
9:10 a.m. - Session I: The Current Landscape of Biosimilars Development, Regulatory Review, and Stakeholder Education
9:10 a.m. - FDA’s Perspective on the Regulation of Biosimilars
Leah Christl, U.S. Food and Drug Administration
9:30 a.m. - Manufacturer Experiences with Biosimilar Development
Carlos Sattler, Sandoz, Inc.
9:50 a.m. - Panel Discussion
Moderator: Robert Rifkin, The U.S. Oncology Network
10:20 a.m. - Moderated Discussion and Audience Q&A
10:50 a.m. - Break
11:00 a.m. - Session II: Addressing Challenges in Clinical Decision-Making, Coverage and Reimbursement, and Postmarket Evidence Development
12:00 p.m. - Moderated Discussion and Audience Q&A
12:30 p.m. - Closing Remarks